A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

应世生物同时还展示了另一款创新药IN30758的临床前研究数据。IN30758是一种针对多种实体瘤的全球首创靶点ADC药物。IN30758在多种癌症的临床前CDX和PDX模型中都显示出强大的体内疗效，并且在灵长类中展现出的良好耐受性。IN30758预 ...